BioCentury
ARTICLE | Product Development

Two for one in neuroblastoma

Apeiron combines GD2 mAb with local delivery of IL-2 for neuroblastoma

February 28, 2011 8:00 AM UTC

By activating multiple elements of the host's immune system, Apeiron Biologics AG believes its mAb fused to IL-2 will provide a one-two punch to neuroblastoma cells, without the toxic side effects of systemic IL-2 treatment.

The biotech this month obtained rights to develop and commercialize hu14.18-IL2 from Merck KGaA, which had decided not to develop the candidate due to pipeline prioritization, according to Apeiron CFO Lukas Kadawy...